Antenatal Magnesium Sulfate Use for Fetal Neuroprotection: Experience from a Tertiary Care Hospital in Turkey

Basit Öğe Kaydı
dc.authoridMELEKOGLU, RAUF/0000-0001-7113-6691
dc.authoridÇOLAK, CEMİL/0000-0001-5406-098X
dc.authorwosidMELEKOGLU, RAUF/AAF-1614-2019
dc.authorwosidSimsek, Yavuz/AAH-9894-2021
dc.authorwosidÇOLAK, CEMİL/ABI-3261-2020
dc.contributor.authorRauf, Melekoglu
dc.contributor.authorSevil, Eraslan
dc.contributor.authorEbru, Celik
dc.contributor.authorYavuz, Simsek
dc.contributor.authorCemil, Colak
dc.date.accessioned2024-08-04T20:43:00Z
dc.date.available2024-08-04T20:43:00Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAims: We aimed to demonstrate the effect of magnesium sulfate for fetal neuroprotection on maternal and neonatal outcomes of pregnants delivered before 32 weeks. Materials and methods: The records of 107 patients who were delivered before 32 weeks of pregnancy were reviewed retrospectively during the period between January 2011-February 2016. Patients who were treated with MgSO4 for fetal neuroprotective effect constituted the study group, and patients who were not received MgSO4 for the fetal neuroprotection represented the control group. Results: One hundred seven women delivered before 32nd weeks of pregnancy met study criteria and of these patients, 46 were formed the magnesium sulfate group, and the remaining 61 were constituted the control group. The age (28.37 +/- 4.97 versus 29.90 +/- 5.23 respectively; p= 0.129), body mass index (BMI) (26.25 +/- 4.12 versus 26.90 +/- 5.68 respectively; p= 0.342) and gestational age at delivery (28.08 +/- 2.66 versus 28.78 +/- 2.15 respectively; p= 0.136) were similar between the groups. Intraventricular hemorrhage was more common in control group compared with the MgSO4 group [7/61 (11.4%) versus 3/46 (6.5%); p= 0.049]. For the periventricular leukomalacia [1 (2.2%) versus 0 (0%) respectively; p= 0.430], neonatal convulsion [1 (2.2%) versus 3 (4.9%) respectively; P= 0.630] and neonatal encephalopathy [0 (0%) versus 1 (1.6%) respectively; p= 0.570], no substantial differences were seen between the groups. Conclusions: The results of this study suggest that MgSO4 treatment for fetal neuroprotection has a beneficial effect on intraventricular hemorrhage rate. The widespread use of prenatal MgSO4 for the purpose of fetal neuroprotection before 32 weeks of pregnancy at a standard dose protocol could improve the neonatal neurological outcomes.en_US
dc.identifier.endpage1754en_US
dc.identifier.issn0970-938X
dc.identifier.issn0976-1683
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85014310230en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1749en_US
dc.identifier.urihttps://hdl.handle.net/11616/97714
dc.identifier.volume28en_US
dc.identifier.wosWOS:000396830900054en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAllied Acaden_US
dc.relation.ispartofBiomedical Research-Indiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemorrhageen_US
dc.subjectMagnesium sulfateen_US
dc.subjectNeuroprotective agentsen_US
dc.subjectPeriventricular leukomalaciaen_US
dc.subjectPregnancyen_US
dc.titleAntenatal Magnesium Sulfate Use for Fetal Neuroprotection: Experience from a Tertiary Care Hospital in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu